Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $1.83 Average PT from Analysts

Posted by Brenda Bartman on Aug 3rd, 2026

Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) has been assigned a consensus recommendation of “Reduce” from the five ratings firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $1.8333.

PACB has been the topic of several analyst reports. Zacks Research downgraded shares of Pacific Biosciences of California from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pacific Biosciences of California in a research report on Friday, July 17th. Finally, Barclays upped their price target on Pacific Biosciences of California from $1.00 to $1.50 and gave the stock an “underweight” rating in a research note on Monday, May 11th.

Get Our Latest Stock Report on PACB

Pacific Biosciences of California Price Performance

PACB stock opened at $1.40 on Monday. The firm has a 50 day moving average of $1.46 and a two-hundred day moving average of $1.58. Pacific Biosciences of California has a 12 month low of $1.09 and a 12 month high of $2.73. The company has a market capitalization of $434.84 million, a price-to-earnings ratio of -3.26 and a beta of 2.31.

Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. Pacific Biosciences of California had a negative net margin of 80.35% and a negative return on equity of 571.06%. The business had revenue of $37.18 million for the quarter, compared to the consensus estimate of $39.94 million. On average, research analysts expect that Pacific Biosciences of California will post -0.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Pacific Biosciences of California

Large investors have recently added to or reduced their stakes in the stock. Creative Planning raised its position in shares of Pacific Biosciences of California by 245.9% in the second quarter. Creative Planning now owns 175,690 shares of the biotechnology company’s stock valued at $218,000 after purchasing an additional 124,893 shares during the period. Cetera Investment Advisers lifted its stake in shares of Pacific Biosciences of California by 10.1% in the second quarter. Cetera Investment Advisers now owns 104,725 shares of the biotechnology company’s stock worth $130,000 after buying an additional 9,617 shares during the last quarter. Prudential Financial Inc. boosted its holdings in shares of Pacific Biosciences of California by 73.0% during the 2nd quarter. Prudential Financial Inc. now owns 35,684 shares of the biotechnology company’s stock worth $44,000 after buying an additional 15,062 shares during the period. Invesco Ltd. grew its stake in Pacific Biosciences of California by 60.0% in the 2nd quarter. Invesco Ltd. now owns 839,340 shares of the biotechnology company’s stock valued at $1,041,000 after buying an additional 314,697 shares during the last quarter. Finally, HUB Investment Partners LLC acquired a new position in Pacific Biosciences of California in the 2nd quarter valued at $77,000.

Pacific Biosciences of California Company Profile

(Get Free Report)

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.